Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Broadview Ventures

Investor type Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 66
Average round size
info
The average size of a deal this fund participated in
$7M
Portfolio companies 49
Rounds per year 4.71
Lead investments 5
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.26
Exits 6
Key employees 6
Stages of investment
Early Stage Venture
Private Equity
Seed

Areas of investment

  • Health Care
  • Biotechnology
  • Medical Device
  • Therapeutics
  • Medical
Summary

Broadview Ventures appeared to be the VC, which was created in 2008. The leading representative office of defined VC is situated in the Boston. The fund was located in North America if to be more exact in United States.

Comparing to the other companies, this Broadview Ventures performs on 17 percentage points less the average number of lead investments. The higher amount of exits for fund were in 2017. The fund is constantly included in 2-6 deals per year. Speaking about the real fund results, this VC is 1 percentage points more often commits exit comparing to other organizations. The high activity for fund was in 2014. Despite it in 2019 the fund had an activity. Deals in the range of 1 - 5 millions dollars are the general things for fund. When the investment is from Broadview Ventures the average startup value is 5-10 millions dollars.

The standard case for the fund is to invest in rounds with 2-3 partakers. Despite the Broadview Ventures, startups are often financed by Boulder Ventures, Atlas Venture, Amgen Ventures. The meaningful sponsors for the fund in investment in the same round are Boulder Ventures, Atlas Venture, Amgen Ventures. In the next rounds fund is usually obtained by Remeditex Ventures, Boulder Ventures, Atlas Venture.

Among the most popular portfolio startups of the fund, we may highlight 480 Biomedical, Capricor Therapeutics, InfoBionic. The fund has no exact preference in some founders of portfolio startups. When startup sums 4 or 5+ of the founder, the probability for it to get the investment is little. Among the most successful fund investment fields, there are Therapeutics, Medical Device. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.

The fund was created by Christopher Colecchi. The overall number of key employees were 6.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Broadview Ventures:
Typical Co-investors
Broadview Ventures is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Broadview Ventures:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Asukanet Hiroshima, Hiroshima Prefecture, Japan
Chuangkun Investment Management China, Hangzhou, Zhejiang
Industrial Securities China, Fuzhou, Jiangxi
Mogility Capital -
Nanosys California, Milpitas, United States
Shanghai Zheshang Shangwu Zixun Youxian Gongsi China, Shanghai
SnowMark Corporation Florida, United States, Vero Beach
The Provident Bank Amesbury, Massachusetts, United States
ZEMU Venture Capital -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

RapidPulse

Health Care
Medical Device
$10M31 Aug 2022 Miami, Florida, United States

XII Medical

Health Care
Medical Device
Wellness
$30M05 May 2022 Union City, California, United States

HAYA Therapeutics

Biopharma
Biotechnology
Health Care
Medical
$5M09 Feb 2022 Lausanne, Vaud, Switzerland

CroíValve

Medical Device
$9M04 Feb 2022 Dublin, County Dublin, Ireland

Kantum Bio

Biopharma
Biotechnology
Health Care
Therapeutics
$3M12 Jul 2021 Concord, New Hampshire, United States

RapidPulse

Health Care
Medical Device
$15M23 Jun 2021 Miami, Florida, United States

FineHeart

Biotechnology
Health Care
Medical
Medical Device
$17M01 Jun 2021 Bordeaux, New Aquitaine, France

HAYA Therapeutics

Biopharma
Biotechnology
Health Care
Medical
$19M20 May 2021 Lausanne, Vaud, Switzerland

Biotechnology
Health Care
Pharmaceutical
Therapeutics
$5M07 Dec 2020 Durham, North Carolina, United States
News
RapidPulse Raises $15M in Series A Funding

– RapidPulse from Miami FL raised $15M in Series A funding.
– The round was led by Santé Ventures with participation from Epidarex Capital, Hatteras Venture Partners, Broadview Ventures, and Syntheon.
– The company plans to use the funds to advance its system through expanded clinical evaluation and build out its platform of proprietary catheters.

HAYA Therapeutics Completes CHF 18 Million Seed Financing To Advance Anti-fibrotic Therapies Targeting Long Non-coding RNAs

– HAYA Therapeutics, SA, a company developing precision medicines that target tissue and cell-specific long non-coding RNAs (lncRNAs), announced the successful closing of its CHF 18 million seed round.
– The financing was led by Broadview Ventures, with participation from Apollo Health Ventures, BERNINA BioInvest, 4See Ventures, Schroder Adveq and Viva BioInnovator.
– Founded and led by a team of experts in lncRNA biology and fibrotic disease, HAYA will use the funds from the financing to advance the discovery and development of innovative organ and cell-selective therapeutics that target lncRNAs to treat and potentially reverse fibrosis and other serious medical conditions related to aging.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Broadview Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: